EXEL SEC Filing News — Exelixis, Inc.

Latest SEC filings for Exelixis, Inc. (EXEL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-11.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin…
Sector: Healthcare Industry: Biotechnology Market Cap: $15.5B
20
Total Filings
0
Bullish Classifications
3
Bearish Classifications
13
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for EXEL currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
EXEL Filing Activity Snapshot 2026-05-29 — 2026-09-11
Insider Transactions (Form 4)
0 buys vs 3 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$526.5K
Beckerle Mary C (Director) · 2026-08-12
9,812 shares · Form 4
Form 144 Notices
3
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Exelixis, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 10 compensation award and 3 open-market sale. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×10
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-08-12

EXEL insider Beckerle Mary C (Director) sold 9,812 shares (~$526.5K)

Beckerle Mary C, listed as Director at EXELIXIS, INC., reported an open-market sale of 9,812 EXEL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,812 $53.66 $526.5K
Filing: Form 4 (Insider Transaction) Insider: Beckerle Mary C (Director) Shares: 9,812 Est. Value: $526.5K
Form 4 Open-market sale Insider Selling 2026-06-03

EXEL insider WYSZOMIERSKI JACK L (Director) sold 3,925 shares (~$198.4K)

WYSZOMIERSKI JACK L, listed as Director at EXELIXIS, INC., reported an open-market sale of 3,925 EXEL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,925 $50.55 $198.4K
Filing: Form 4 (Insider Transaction) Insider: WYSZOMIERSKI JACK L (Director) Shares: 3,925 Est. Value: $198.4K
Form 4 Open-market sale Insider Selling 2026-06-03

EXEL insider Eckhardt Sue Gail (Director) sold 9,812 shares (~$492.0K)

Eckhardt Sue Gail, listed as Director at EXELIXIS, INC., reported an open-market sale of 9,812 EXEL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,812 $50.14 $492.0K
Filing: Form 4 (Insider Transaction) Insider: Eckhardt Sue Gail (Director) Shares: 9,812 Est. Value: $492.0K
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

PAPADOPOULOS STELIOS (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: PAPADOPOULOS STELIOS (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Heyman Tomas J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Heyman Tomas J. (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Eckhardt Sue Gail (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Eckhardt Sue Gail (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Smith Julie (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Smith Julie (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Freire Maria C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Freire Maria C (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Beckerle Mary C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Beckerle Mary C (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

Oliver Bob (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: Oliver Bob (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

WYSZOMIERSKI JACK L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: WYSZOMIERSKI JACK L (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

POSTE GEORGE (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 8,367 — —
Filing: Form 4 (Insider Transaction) Insider: POSTE GEORGE (Director) Shares: 8,367
Form 4 Compensation award Tax / Compensation Filing 2026-05-29

EXEL insider Form 4 filed for equity award, exercise, or tax withholding

JOHNSON DAVID EDWARD (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Option (right to buy) 19,133 — —
Filing: Form 4 (Insider Transaction) Insider: JOHNSON DAVID EDWARD (Director)
Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Exelixis, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-10

EXEL Form 144 filed for proposed insider sale by MARY BECKERLE (9,812 shares) ~$526.5K

MARY BECKERLE filed a Form 144 with the SEC indicating intent to sell EXEL (EXELIXIS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MARY BECKERLE Shares: 9,812 Est. Value: $526.5K
Form 144 Proposed Insider Sale 2026-06-01

EXEL Form 144 filed for proposed insider sale by Eckhardt Sue Gail (9,812 shares) ~$499.1K

Eckhardt Sue Gail filed a Form 144 with the SEC indicating intent to sell EXEL (EXELIXIS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Eckhardt Sue Gail Shares: 9,812 Est. Value: $499.1K
Form 144 Proposed Insider Sale 2026-06-01

EXEL Form 144 filed for proposed insider sale by JACK L WYSZOMIERSKI (3,925 shares) ~$198.4K

JACK L WYSZOMIERSKI filed a Form 144 with the SEC indicating intent to sell EXEL (EXELIXIS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JACK L WYSZOMIERSKI Shares: 3,925 Est. Value: $198.4K
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Exelixis, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-11

EXEL filed 8-K — material company event

EXELIXIS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-08-31

EXEL filed 8-K — material company event

EXELIXIS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Form 8-K Material Company Update 2026-08-05

EXEL filed 8-K — material company event

EXELIXIS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Exelixis, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

EXEL filed Quarterly Report (10-Q)

EXELIXIS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

How we classify Exelixis, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on EXEL. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — EXEL SEC Filings

More Tools for EXEL

Want deeper EXEL analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the EXEL stock analysis page.

EXEL Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer